Dyne Therapeutics, Inc.
DYNNASDAQHealthcare● Active
$17.11
+$0.07(+0.41%)
Market Cap$2.8B
P/E Ratio—
52W High$25
52W Low$8.06
Dyne Therapeutics, Inc. (DYN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DYN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.40B | $0.28B | $0.21B | $0.14B | $0.12B |
| G&A Expenses | $0.07B | $0.06B | $0.03B | $0.03B | $0.03B |
| Total Operating Expenses | $0.47B | $0.34B | $0.24B | $0.17B | $0.15B |
| Operating Income | ($0.47B) | ($0.34B) | ($0.24B) | ($0.17B) | ($0.15B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.03B | $0.03B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.45B) | ($0.32B) | ($0.24B) | ($0.17B) | ($0.15B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.45B) | ($0.32B) | ($0.24B) | ($0.17B) | ($0.15B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 |
| Wtd Avg Shares | 0.13B | 0.09B | 0.06B | 0.05B | 0.05B |
| EBITDA | ($0.44B) | ($0.32B) | ($0.23B) | ($0.17B) | ($0.15B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Dyne Therapeutics, Inc. data
About Dyne Therapeutics, Inc. (DYN) Income Statement
Dyne Therapeutics, Inc. (DYN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DYN reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.45B) — a net profit margin of —.
Frequently asked questions
DYN · 4 questionsDyne Therapeutics, Inc. (DYN) reported revenue of $0.00B for 2025, down —% year-over-year.
DYN revenueDYN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08